Home / Stocks / SGRY

Surgery Partners (SGRY, Hospitals & clinics) Stock Valuation & Fair Value

Significantly overvalued

Surgery Partners (SGRY, Hospitals & clinics) trades at a current P/E of 63.8, about 90% above its historical normal valuation, with a forward growth estimate of 17.6% and a PEG of 3.61. Analysts' one-year estimates have been hit 10% of the time. Priced at its historical normal P/E of 33.6 on the same blended earnings, the 2026-11-06 close of $23.20 corresponds to about $12.20 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-07
Current P/E
63.8
Normal P/E
33.6
PEG
3.61
Fwd growth
17.6%
Div yield
0.0%
RSI (14)
—

Valuation flags

Verdict history

tickerseer's rating moved from mixed on our tests (2026-08-07) to poor on forward returns (2026-10-19). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

Current P/E and rating by weekCurrent P/E moved from 33.2 to 32.2 between 2026-08-07 and 2026-10-16, against a normal P/E of 33.6, with 4 rating changes over 11 recorded weeks.2026-08-07: P/E 33.2, Mixed on our tests, recalculated for the week of 2026-08-072026-08-07: P/E 34.6, Mixed on our tests, recorded live 2026-08-102026-08-14: P/E 34.6, Mixed on our tests, recalculated for the week of 2026-08-142026-08-14: P/E 32.8, Mixed on our tests, recorded live 2026-08-172026-08-21: P/E 32.8, Mixed on our tests, recalculated for the week of 2026-08-212026-08-21: P/E 31.8, Mixed on our tests, recorded live 2026-08-242026-08-27: P/E 31.8, Mixed on our tests, recalculated for the week of 2026-08-272026-08-28: P/E 31.8, Mixed on our tests, recalculated for the week of 2026-08-282026-08-28: P/E 31.8, Mixed on our tests, recalculated for the week of 2026-08-302026-08-28: P/E 30.0, Mixed on our tests, recorded live 2026-08-312026-09-04: P/E 30.0, Mixed on our tests, recalculated for the week of 2026-09-052026-09-04: P/E 31.2, Mixed on our tests, recorded live 2026-09-072026-09-11: P/E 31.2, Mixed on our tests, recalculated for the week of 2026-09-122026-09-11: P/E 31.5, Mixed on our tests, recorded live 2026-09-142026-09-18: P/E 31.5, Mixed on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 29.1, Weak on forward returns, recorded live 2026-09-212026-09-25: P/E 29.1, Weak on forward returns, recalculated for the week of 2026-09-262026-09-25: P/E 31.6, Poor on forward returns, recorded live 2026-09-282026-10-02: P/E 31.6, Poor on forward returns, recalculated for the week of 2026-10-032026-10-02: P/E 29.3, Weak on forward returns, recorded live 2026-10-052026-10-09: P/E 29.3, Weak on forward returns, recalculated for the week of 2026-10-102026-10-09: P/E 30.6, Poor on forward returns, recorded live 2026-10-122026-10-16: P/E 30.6, Poor on forward returns, recalculated for the week of 2026-10-172026-10-16: P/E 32.2, Poor on forward returns, recorded live 2026-10-1930.032.034.0Aug 7Aug 25Sep 11Sep 28Oct 16Normal P/E 33.6
Mixed on our testsWeak on forward returnsPoor on forward returnsLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-08-07P/E 33.2-1%Mixed on our tests (recalculated)
2026-08-10P/E 34.6+3%Mixed on our tests
2026-09-21P/E 29.1-13%Weak on forward returns
2026-09-28P/E 31.6-6%Poor on forward returns (across a rating rules change)
2026-10-05P/E 29.3-13%Weak on forward returns
2026-10-12P/E 30.6-9%Poor on forward returns (across a rating rules change)
2026-10-19P/E 32.2-4%Poor on forward returns ← now
Show all 24 readings
WeekCurrent P/EPremium to normal P/ERating
2026-08-07P/E 33.2-1%Mixed on our tests (recalculated)
2026-08-10P/E 34.6+3%Mixed on our tests
2026-08-14P/E 34.6+3%Mixed on our tests (recalculated)
2026-08-17P/E 32.8-2%Mixed on our tests
2026-08-21P/E 32.8-2%Mixed on our tests (recalculated)
2026-08-24P/E 31.8-5%Mixed on our tests
2026-08-27P/E 31.8-5%Mixed on our tests (recalculated)
2026-08-28P/E 31.8-5%Mixed on our tests (recalculated)
2026-08-30P/E 31.8-5%Mixed on our tests (recalculated)
2026-08-31P/E 30.0-11%Mixed on our tests
2026-09-05P/E 30.0-11%Mixed on our tests (recalculated)
2026-09-07P/E 31.2-7%Mixed on our tests
2026-09-12P/E 31.2-7%Mixed on our tests (recalculated)
2026-09-14P/E 31.5-6%Mixed on our tests
2026-09-19P/E 31.5-6%Mixed on our tests (recalculated)
2026-09-21P/E 29.1-13%Weak on forward returns
2026-09-26P/E 29.1-13%Weak on forward returns (recalculated)
2026-09-28P/E 31.6-6%Poor on forward returns (across a rating rules change)
2026-10-03P/E 31.6-6%Poor on forward returns (recalculated)
2026-10-05P/E 29.3-13%Weak on forward returns
2026-10-10P/E 29.3-13%Weak on forward returns (recalculated)
2026-10-12P/E 30.6-9%Poor on forward returns (across a rating rules change)
2026-10-17P/E 30.6-9%Poor on forward returns (recalculated)
2026-10-19P/E 32.2-4%Poor on forward returns ← now

Frequently asked questions

Is Surgery Partners stock overvalued?

At a current P/E of 63.8 versus its historical normal P/E of 33.6, Surgery Partners trades about 90% above its typical valuation, with a PEG of 3.61 on 17.6% forward growth. tickerseer currently rates it significantly overvalued.

What is Surgery Partners's fair value and PEG?

Surgery Partners trades at a current P/E of 63.8 against a historical normal P/E of 33.6, a PEG of 3.61, and a forward growth estimate of 17.6%. Priced at its historical normal P/E of 33.6 on the same blended earnings, the 2026-11-06 close of $23.20 corresponds to about $12.20 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Surgery Partners changed?

tickerseer's rating moved from mixed on our tests (2026-08-07) to poor on forward returns (2026-10-19). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

Industry: Hospitals & clinics. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track SGRY free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.